An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inflammatory Atherosclerosis: Characteristics of the Injurious Agent.
Frink RJ.
Sacramento (CA): Heart Research Foundation; 2002.
Top results in this bookTable of Contents
Noninvasive Testing for Coronary Artery Disease [Internet].
Skelly AC, Hashimoto R, Buckley DI, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Mar. (Comparative Effectiveness Reviews, No. 171.)
Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease [Internet].
Bravata DM, McDonald KM, Gienger AL, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Oct. (Comparative Effectiveness Reviews, No. 9.)
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Clinical Review Report: Ticagrelor (Brilinta) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.
Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].
Guirguis-Blake JM, Evans CV, Redmond N, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. (Evidence Synthesis, No. 165.)
Screening for Asymptomatic Carotid Artery Stenosis in the General Population: An Evidence Update for the U.S. Preventive Services Task Force [Internet].
Guirguis-Blake JM, Webber EM, Coppola EL.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Feb. (Evidence Synthesis, No. 199.)
Future Research Needs for the Comparison of Percutaneous Coronary Interventions with Bypass Graft Surgery in Nonacute Coronary Artery Disease: Identification of Future Research Needs from Comparative Effectiveness Review No. 9 [Internet].
Trikalinos TA, Dahabreh IJ, Wong J, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Sep. (Future Research Needs Papers, No. 1.)
Renal Artery Stenosis Management Strategies: An Updated Comparative Effectiveness Review [Internet].
Balk EM, Raman G, Adam GP, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. (Comparative Effectiveness Reviews, No. 179.)
Clinical Review Report: Rivaroxaban (Xarelto): Bayer Inc. Indication: In combination with 75 mg to 100 mg acetylsalicylic acid, for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease with or without peripheral artery disease [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan.
Treatment Strategies for Women With Coronary Artery Disease: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 66 [Internet].
Dolor RJ, Patel MR, Melloni C, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb. (Future Research Needs Papers, No. 42.)
Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 58 [Internet].
Sanders GD, Patel MR, Chatterjee R, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb. (Future Research Needs Papers, No. 41.)
Pharmacoeconomic Review Report: Ticagrelor (Brilinta) [Internet].
Pharmacoeconomic Review Report: Rivaroxaban (Xarelto): (Bayer Inc.): Indication: In combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD) [Internet].
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Excimer Laser and Stenting in Patients with Distal Peripheral Arterial Disease: A Review of the Clinical Effectiveness, Safety, and Guidelines [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jan 26.
Telehealth for Patients with Hypertension, Coronary Artery Disease or Implantable Cardiac Devices: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Jan 27.
Peripheral Arterial Disease: Diagnosis and Management: [A] Evidence review for determining diagnosis and severity of PAD in people with diabetes.
London: National Institute for Health and Care Excellence (NICE); 2018 Feb. (NICE Guideline, No. 147.)
Bioabsorbable Stents for Adults with Coronary Artery Disease: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Dec 10.
Vulnerable Atherosclerotic Plaque [Internet].
Alsheikh-Ali AA, Kitsios GD, Balk EM, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Aug. (Comparative Effectiveness Technical Briefs, No. 3.)
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on